Phaseline

Companies › Tonix Pharmaceuticals

Tonix Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Other, Psychiatry; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cyclobenzaprine Hydrochloride (TNX-102)
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
HTR2A, HTR2CPhase 2Major Depressive Episode (MDE); PharmakokineticFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07413367Cyclobenzaprine Hydrochloride (TNX-102)Phase 1PharmakokineticOtherFeb 2026
NCT07621237Cyclobenzaprine Hydrochloride (TNX-102)Phase 2Major Depressive Episode (MDE)PsychiatryFeb 2028

From the company's SEC filings

Cash of $163m on 2026-09-30; operating cash outflow about $169m a year; runway about 12 months at that burn, to Sep 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Targets

HTR2A (1) HTR2C (1)

Companies with the same targets

Boryung Pharmaceutical Cybin IRL COMPASS Pathways ACADIA Pharmaceuticals Vanda Pharmaceuticals Intra-Cellular Therapies Definium Therapeutics US Sichuan Kelun Pharmaceutical Otsuka NeuroRx

Companies built like this

Clear Scientific Syndeio Biosciences NeuroRx MapLight Therapeutics COMPASS Pathways

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.